Elsevier Progresses in Open-Access Deal Making

The scholarly publisher has announced several new licensing agreements in both Europe and the US—but some major academic groups are still without contracts and access to journals.

Written byDiana Kwon
| 7 min read
carnegie mellon university library elsevier wiley academic scholarly publishing open access

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

ABOVE: Carnegie Mellon University library
WIKIMEDIA, DLLU

Last summer, dozens of academic institutions in Sweden let their Elsevier subscriptions lapse, forgoing permission to read new content in the scholarly publisher’s journals. Like other groups in Europe and the US, they were pushing for increased open access and contained costs—and had reached a deadlock in negotiations with the publisher. On Friday (November 22), the two sides announced that they had finally come to an agreement, establishing a so-called transformative deal that includes access to paywalled articles and open-accessing publishing into one fee.

“We had a lot of [informal] discussions with Elsevier during the cancellation and we started to negotiate again in the summer,” says Wilhelm Widmark, the library director at Stockholm University and a member of the steering committee for the Bibsam consortium, which negotiates on behalf of more than 80 Swedish institutions. “I think Elsevier has become more flexible during the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies